Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Multidrug resistance (MDR) in cancer is often linked to the overexpression of drug efflux pumps like P-glycoprotein (P-gp).
• Current P-gp inhibitors face challenges including toxicity, drug interactions, and poor pharmacokinetics, limiting their clinical use.
• Novel strategies are needed to inhibit P-gp activity or expression to improve cancer treatment efficacy.

Approach:

• This review examines the P-gp modulatory effects (inhibition of function and expression) of curcumin and its synthetic analogs.
• It compares the efficacy and stability of various curcumin derivatives in preclinical models.
• The focus is on identifying compounds with improved pharmacological profiles over native curcumin.

Key Points:

• Curcumin, derived from *Curcuma longa*, exhibits P-gp inhibitory and expression-modulating properties.
• Curcumin analogs are being developed to enhance stability and maintain P-gp modulatory activity.
• Several curcumin analogs show promise in preclinical studies for overcoming P-gp-mediated MDR.

Conclusions:

• Curcumin and its analogs represent a promising class of compounds for developing new P-gp inhibitors.
• Further research into these analogs could lead to safer and more effective treatments for overcoming multidrug resistance in human cancers.
• Targeting P-gp with curcumin-based compounds offers a potential strategy to enhance chemotherapy efficacy.